NEW YORK (GenomeWeb News) – Abbott Laboratories today reported that its fourth quarter 2013 molecular diagnostics sales were flat year over year as its overall diagnostics sales increased 6 percent.

The firm posted MDx sales of $131 million for the quarter, flat with Q4 2012. It said that foreign exchange trimmed nearly 1 percent off its MDx revenues for the quarter. However, its international MDx sales were up around 10 percent on an operational basis, driven by "continued strong growth in infectious disease testing, particularly in emerging markets."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.